American Cancer Society Issues Updated Guidelines for Prostate Cancer Screening

The American Cancer Society updated its guidelines, recommending proactive PSA blood tests for men starting at age 50 to improve early prostate cancer detection and reduce mortality.

American Cancer Society Issues Updated Guidelines for Prostate Cancer Screening
Photo-illustration WireIsrael: AI Generated

A major update to early detection guidelines for prostate cancer could transform diagnostic protocols for one of the most common malignancies among men. The American Cancer Society (ACS) released updated recommendations advising proactive, periodic blood testing starting at age 50. Unlike previous guidance that relied on shared decision-making between patients and physicians regarding whether to test, the updated framework actively recommends routine screening after explaining the associated benefits and potential risks. This shift stems from long-term studies indicating a reduction in disease mortality and a lower rate of cases diagnosed at advanced stages.

New Screening Guidelines and Risk Categories

Under the revised recommendations, men at average risk for prostate cancer should undergo a prostate-specific antigen (PSA) blood test every two years from age 50 through 69. The PSA test measures the level of a protein produced by the prostate gland, where elevated levels can indicate cancer or non-malignant conditions such as benign prostatic hyperplasia or inflammation. For individuals at heightened risk, the organization advises initiating screenings earlier, at age 45.

Men whose father, brother, or son was diagnosed with prostate cancer before age 65, or who have more than one first-degree relative affected by the disease, fall into a higher-risk category. For this group, annual testing is recommended up to age 69. Conversely, when only a single first-degree relative is diagnosed at age 65 or older, testing every two years starting at age 45 is advised. In the USA, annual screening from age 45 is also recommended for Black men due to higher incidence and mortality rates observed within this population. For men aged 70 to 74, a personalized decision with a physician is recommended based on overall health status and potential risks, while routine screening is generally not recommended for individuals aged 75 and older.

Scientific Rationale and the Shift from Digital Rectal Exams

This policy evolution follows more than a decade of medical debate concerning the utility of PSA testing. Previous concerns focused on the possibility that widespread screening would lead to the detection of non-life-threatening tumors and unnecessary treatments with significant side effects. However, recent years have yielded robust research supporting the advantages of early detection.

A large-scale European study that followed men for 23 years found that PSA-based screening correlated with an estimated 13% relative reduction in prostate cancer mortality among men aged 55 to 69. This indicates that screening can save lives by identifying significant tumors before they metastasize. Nevertheless, the organization emphasizes that modern clinicians possess advanced diagnostic tools to minimize invasive procedures and unneeded interventions.

Another notable update involves dropping the digital rectal exam as a routine screening tool. According to the guidance, the PSA test proves more effective as an initial screening measure, whereas physical exams offer little added benefit for early detection in men with low PSA levels, though physicians retain discretion in specific clinical contexts.

Managing Elevated Results and the Situation in Israel

The updated guidelines stress that an elevated PSA level does not automatically indicate a malignant tumor, advising against rushing into a biopsy following a single abnormal result. For men up to age 69 with a PSA level of 3 nanograms per milliliter or higher, the organization recommends repeating the blood test within two to three months before pursuing further evaluation. If the value remains high, a prostate MRI or additional biomarker tests can be considered. Furthermore, low-risk tumors that are not expected to progress rapidly often warrant active surveillance rather than immediate treatment to avoid side effects.

Prostate cancer remains the most prevalent cancer among Israeli men. According to Ministry of Health data published in September 2026, 3,421 new cases were diagnosed in Israel during 2023, while 520 men died from the disease, and approximately 14,500 men were living with a diagnosis received within the preceding five years. Unlike the new American guidelines, Israel currently lacks a national screening program for universal PSA testing across all men aged 50. According to the Israel Cancer Association, men aged 55 to 69 are advised to consult their physician regarding the test while weighing early detection benefits against potential risks. While the new American guidelines do not automatically alter Israeli protocol, they are expected to spark renewed discussion regarding local early detection policies.

Related News